JP2018519818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519818A5 JP2018519818A5 JP2017566354A JP2017566354A JP2018519818A5 JP 2018519818 A5 JP2018519818 A5 JP 2018519818A5 JP 2017566354 A JP2017566354 A JP 2017566354A JP 2017566354 A JP2017566354 A JP 2017566354A JP 2018519818 A5 JP2018519818 A5 JP 2018519818A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- composition
- lipid
- mixture
- dodap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 150000002632 lipids Chemical class 0.000 claims 16
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 7
- 230000009368 gene silencing by RNA Effects 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- -1 nucleic acid compound Chemical class 0.000 claims 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 5
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims 5
- 102000000412 Annexin Human genes 0.000 claims 4
- 108050008874 Annexin Proteins 0.000 claims 4
- 108050005845 Annexin A11 Proteins 0.000 claims 4
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims 4
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims 4
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical group C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 3
- 101000614345 Homo sapiens Prolyl 4-hydroxylase subunit alpha-1 Proteins 0.000 claims 2
- 102100040477 Prolyl 4-hydroxylase subunit alpha-1 Human genes 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001841 cholesterols Chemical class 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000003611 tocopherol derivatives Chemical class 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562190583P | 2015-07-09 | 2015-07-09 | |
| US62/190,583 | 2015-07-09 | ||
| PCT/US2016/041776 WO2017008076A1 (en) | 2015-07-09 | 2016-07-11 | Compositions and methods for treating lung diseases and lung injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519818A JP2018519818A (ja) | 2018-07-26 |
| JP2018519818A5 true JP2018519818A5 (enExample) | 2019-09-12 |
| JP6884714B2 JP6884714B2 (ja) | 2021-06-09 |
Family
ID=57686097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566354A Active JP6884714B2 (ja) | 2015-07-09 | 2016-07-11 | 肺疾患及び肺損傷を治療するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180200186A1 (enExample) |
| EP (1) | EP3319976B1 (enExample) |
| JP (1) | JP6884714B2 (enExample) |
| AU (2) | AU2016291228B2 (enExample) |
| CA (1) | CA2989884A1 (enExample) |
| ES (1) | ES2898340T3 (enExample) |
| WO (1) | WO2017008076A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2798263T3 (es) | 2005-12-08 | 2020-12-10 | Insmed Inc | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| WO2014085526A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
| PL3060041T3 (pl) | 2013-10-25 | 2021-08-02 | Insmed Incorporated | Związki prostacykliny |
| PL3142643T3 (pl) | 2014-05-15 | 2019-12-31 | Insmed Incorporated | Sposoby leczenia zakażeń płuc prątkami niegruźliczymi |
| EP3773505A4 (en) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS |
| AU2019262117C1 (en) | 2018-05-02 | 2024-12-05 | Insmed Incorporated | Methods for the manufacture of liposomal drug formulations |
| WO2020018959A1 (en) * | 2018-07-19 | 2020-01-23 | Impel Neuropharma, Inc. | Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease |
| GB2592505B (en) * | 2018-09-04 | 2023-05-03 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
| JP7555123B2 (ja) | 2018-10-09 | 2024-09-24 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法 |
| CN109432047B (zh) * | 2018-10-29 | 2021-07-20 | 中国药科大学 | 一种逆转肺纤维化纳米制剂及其制备方法 |
| JP7455144B2 (ja) | 2019-04-29 | 2024-03-25 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 |
| JP7674354B2 (ja) * | 2019-12-05 | 2025-05-09 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法 |
| MX2022012683A (es) | 2020-04-09 | 2023-01-11 | Verve Therapeutics Inc | Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades. |
| CN115768438A (zh) * | 2020-07-10 | 2023-03-07 | 盖纳万科学有限公司 | 用于向肺递送治疗剂的脂质纳米颗粒 |
| JP2023549011A (ja) | 2020-09-15 | 2023-11-22 | ヴァーヴ・セラピューティクス，インコーポレーテッド | 遺伝子編集のための脂質製剤 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| WO2022204219A1 (en) | 2021-03-22 | 2022-09-29 | Recode Therapeutics, Inc. | Compositions and methods for targeted delivery to cells |
| CN113058042B (zh) * | 2021-04-01 | 2023-06-30 | 易慧生物技术(上海)有限公司 | 一种可鼻喷的稳定递载rna分子的脂质纳米颗粒制备方法 |
| CN115245559A (zh) * | 2021-04-25 | 2022-10-28 | 上海萨美细胞技术有限公司 | 一种用于治疗肺损伤的药物 |
| CN117881789A (zh) * | 2021-06-09 | 2024-04-12 | 瑞科德治疗公司 | 多核苷酸组合物、相关制剂、及其使用方法 |
| US20230057155A1 (en) * | 2021-08-11 | 2023-02-23 | Board Of Regents, The University Of Texas System | Dry liposome formulations and related methods thereof |
| PL438742A1 (pl) * | 2021-08-14 | 2023-02-20 | Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością | Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną |
| EP4226949A1 (en) * | 2022-02-14 | 2023-08-16 | Pantherna Therapeutics GmbH | Preparation for use in a method for the treatment and/or prevention of a disease |
| WO2024242216A1 (ko) * | 2023-05-23 | 2024-11-28 | 주식회사 케이더블유바이오 | 대식세포 표적화 리포좀 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
| US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| KR20060036119A (ko) * | 2003-08-20 | 2006-04-27 | 가부시키가이샤 로코모젠 | 시노비올린 활성 조절 작용의 검출 방법 |
| US20060134189A1 (en) * | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
| JP5777519B2 (ja) * | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| WO2011108955A1 (en) * | 2010-03-03 | 2011-09-09 | Universidade De Coimbra | Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s) |
| AU2011261434B2 (en) * | 2010-06-02 | 2015-11-26 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US20140308304A1 (en) * | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| WO2014052634A1 (en) * | 2012-09-27 | 2014-04-03 | The University Of North Carolina At Chapel Hill | Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof |
-
2016
- 2016-07-11 CA CA2989884A patent/CA2989884A1/en not_active Abandoned
- 2016-07-11 EP EP16822088.7A patent/EP3319976B1/en active Active
- 2016-07-11 WO PCT/US2016/041776 patent/WO2017008076A1/en not_active Ceased
- 2016-07-11 JP JP2017566354A patent/JP6884714B2/ja active Active
- 2016-07-11 ES ES16822088T patent/ES2898340T3/es active Active
- 2016-07-11 US US15/742,812 patent/US20180200186A1/en not_active Abandoned
- 2016-07-11 AU AU2016291228A patent/AU2016291228B2/en active Active
-
2020
- 2020-05-22 AU AU2020203367A patent/AU2020203367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519818A5 (enExample) | ||
| Pramanik et al. | Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases | |
| Lu et al. | Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials | |
| Wang et al. | Lipid-based antimicrobial delivery-systems for the treatment of bacterial infections | |
| Chan et al. | Advances in device and formulation technologies for pulmonary drug delivery | |
| JP2007508353A5 (enExample) | ||
| JP2018528184A5 (enExample) | ||
| Jain et al. | Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer | |
| JP2018516545A5 (enExample) | ||
| JP2015523355A5 (enExample) | ||
| JP2015515992A5 (enExample) | ||
| JP2014077003A5 (enExample) | ||
| Jin et al. | Berberine-loaded biomimetic nanoparticles attenuate inflammation of experimental allergic asthma via enhancing IL-12 expression | |
| Homayoonfal et al. | Application of nanoparticles for efficient delivery of quercetin in cancer cells | |
| JP2010508365A5 (enExample) | ||
| Yong et al. | Natural products-based inhaled formulations for treating pulmonary diseases | |
| Abdelaziz et al. | Solid lipid nanoparticle-based drug delivery for lung cancer | |
| Sadhu et al. | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine | |
| Jani et al. | Focused insights into liposomal nanotherapeutics for antimicrobial treatment | |
| JPWO2022066916A5 (enExample) | ||
| Ji et al. | Synaptic vesicle-inspired nanoparticles with spatiotemporally controlled release ability as a “nanoguard” for synergistic treatment of synucleinopathies | |
| TWI760319B (zh) | 乳癌治療 | |
| WO2017019636A1 (en) | Compositions and methods for the treatment of sarcoidosis | |
| Song et al. | Microenvironments‐targeted nanomaterials for atherosclerosis therapy | |
| Guan et al. | Applications of chitosan in pulmonary drug delivery |